POM-V Prescription Required Companion Animal

Meloxicam Ceva 5 mg/ml Solution for Injection for Dogs and Cats

Active ingredient: Meloxicam

Form

Injection

Species

Cats Dogs

Manufacturer

Ceva Sante Animale

VMD MA No.

14966/5008

What it's used for

Dogs: Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Reduction of post-operative pain and inflammation followin...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Meloxicam

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Meloxicam Ceva 5 mg/ml Solution for Injection for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

Dogs:
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal
disorders. Reduction of post-operative pain and inflammation following orthopaedic
and soft tissue surgery.
Cats:
Reduction of post-operative pain after ovariohysterectomy and minor soft tissue
surgery.

Do not use in pregnant or lactating animals.
Do not use in animals suffering from gastrointestinal disorders such as irritation and
haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic
disorders.
Do not use in known cases of hypersensitivity to the active substance or to any of the
excipients.
Do not use in animals less than 6 weeks of age nor in cats of less than 2 kg.

Revised: September 2025
AN: 01833/2025

Dogs:
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Anaphylactoid reaction, Vomiting
, Diarrhoea
,
Blood in faeces
, Appetite loss
, Apathy
Renal failure
Cats:
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Anaphylactoid reaction, Vomiting
, Diarrhoea
,
Blood in faeces
, Appetite loss
, Apathy
Renal failure
1
These side effects disappear following termination of the treatment but in very rare
cases may be serious or fatal.

Revised: September 2025
AN: 01833/2025
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or the national competent authority via the
national reporting system. See also the last section ‘Contact details’ of the package
leaflet

None.

Special precautions for use in animals
If adverse reactions occur, treatment should be discontinued and the advice of a
veterinarian should be sought.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a
potential risk of increased renal toxicity.
Any oral follow-up therapy using meloxicam or other Non Steroidal Anti-Inflammatory
Drugs (NSAIDs) should not be administered in cats, as appropriate dosage regimens
for such follow-up treatments have not been established.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Accidental self-injection may give rise to pain.
People with known hypersensitivity to non- steroidal anti-inflammatory drugs
(NSAIDs) should avoid contact with the veterinary medicinal product.
In view of the risk of accidental self-injection and the known adverse class-effects of
NSAIDs and other prostaglandin inhibitors on pregnancy and/or embryofoetal
development, the veterinary medicinal product should not be administered by
pregnant women or women attempting to conceive.
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
This product can cause eye irritation. In case of contact with the eyes immediately
rinse thoroughly with water.
Special precautions for the protection of the environment:
Not applicable.

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances
with high protein binding may compete for binding and thus lead to toxic effects.
The veterinary medicinal product must not be administered in conjunction with other
NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic
drugs should be avoided.
In animals at anaesthetic risk (e.g. aged animals) intravenous or subcutaneous fluid
therapy during anaesthesia should be taken into consideration. When anaesthesia
and NSAID are concomitantly administered, a risk for renal function cannot be
excluded.
Pre-treatment with anti-inflammatory substances may result in additional or increased
adverse effects and accordingly a treatment-free period with such drugs should be
observed for at least 24 hours before commencement of treatment. The treatment-
free period, however, should take into account the pharmacokinetic properties of the
products used previously.

Do not store above 25°C.

Not applicable.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.